Could COPD drug help control blood sugar? new study explores
NCT ID NCT02363335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial studied how two drugs, roflumilast (used for COPD) and sitagliptin (used for diabetes), affect blood sugar and gut hormones in 29 healthy volunteers aged 21-55. Participants received each drug alone, together, or a placebo, then drank a nutritional shake to measure hormone responses. The goal was to understand how these drugs might lower blood sugar, which could lead to new treatments for type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roflumilast and Sitagliptin
What this could lead to
If successful, this research could point toward new treatments for type 2 diabetes by better understanding how these drugs affect blood sugar and gut hormones.
What could go wrong
This is a small, early-phase study in healthy volunteers, not people with diabetes. The results may not apply to patients or lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States